IRMDIRadimed Corporation

New 3870 pump production ramp compressed margins but bookings doubled shipments.

IRADIMED CORPORATION recently reported past second-quarter 2026 results showing sales of US$20.47 million, slightly higher than a year earlier, alongside lower quarterly net income and earnings per share, while first-half 2026 sales and earnings modestly increased year over year. At the same time, the company issued revenue and earnings guidance for the third quarter and reaffirmed its full‑year 2026 outlook, while maintaining a regular US$0.20 per‑share quarterly dividend, underscoring...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

iRadimed Corp (IRMD) navigates a pivotal transition quarter with robust bookings for its next-generation MRI pump, offset by near-term margin pressure and flat revenue growth.

Moby summary of IRadimed Corporation's Q2 2026 earnings call

iRadimed (NASDAQ:IRMD) reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp. GAAP net income was $5.2 million,

Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q2 2026 investor letter. A copy of the letter is available to download here. In Q2 2026, the Micro Opportunities strategy underperformed the Russell Microcap Index, despite a positive absolute result. The benchmark performed well during a speculative period for micro caps. Over the […]